CalciMedica, a clinical-stage biotechnology company developing CRAC inhibitors for the treatment of inflammatory diseases, announced it has raised $21 Million in Series D Financing to support the clinical development of a portfolio of CRAC channel inhibitors including AuxoraTM which is being evaluated in an ongoing clinical trial in severe and critical COVID-19 pneumonia, and in a Phase 2b trial in acute pancreatitis.
Auxora is currently under evaluation in a blinded, placebo-controlled clinical trial enrolling up to 400 patients with severe and critical COVID-19 pneumonia. To date over 200 patients have been randomized. Patients are receiving either Auxora or matched placebo in addition to standard of care, which includes dexamethasone and may include remdesivir.
Photo by Fusion Medical Animation on Unsplash